
CVRx (CVRX) Stock Forecast & Price Target
CVRx (CVRX) Analyst Ratings
Bulls say
CVRx has demonstrated a robust financial position, exiting Q3 with $100 million in cash, which management believes will support breakeven and facilitate growth initiatives leading into 2025. The company reported a remarkable median increase of 14 implants in the first nine months of 2024, signifying a growth rate of 92% compared to the previous year, indicating strong market demand for its Barostim technology. Additionally, recent positive reimbursement updates are expected to enhance the adoption and utilization of Barostim, further solidifying CVRx's position in an under-penetrated market with significant growth potential.
Bears say
CVRx reported Q3 revenue of $13.4 million, reflecting a 27% year-over-year growth, but the company's adjusted revenue guidance for 2024 fell by $500,000, indicating potential challenges ahead. The high cash burn rate of $9.8 million from operations during the quarter, along with a concentrated operational risk due to reliance on a single facility in Minneapolis, raises concerns about the company's financial stability and ability to meet growing operational demands. Additionally, the competitive landscape poses significant threats, as established medical device companies with greater resources may impact CVRx's market position and hinder long-term growth prospects.
This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.
CVRx (CVRX) Analyst Forecast & Price Prediction
Start investing in CVRx (CVRX)
Order type
Buy in
Order amount
Est. shares
0 shares